Literature DB >> 20861166

The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.

David J Curtis1, Matthew P McCormack.   

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is commonly caused by the overexpression of oncogenic transcription factors in developing T cells. In a mouse model of one such oncogene, LMO2, the cellular effect is to induce self-renewal of committed T cells in the thymus, which persist long-term while acquiring additional mutations and eventually giving rise to leukemia. These precancerous stem cells (pre-CSC) are intrinsically resistant to radiotherapy, implying that they may be refractory to conventional cancer therapies. However, they depend on an aberrantly expressed stem cell-like self-renewal program for their maintenance, in addition to a specialized thymic microenvironmental niche. Here, we discuss potential approaches for targeting pre-CSCs in T-ALL by using therapies directed at oncogenic transcription factors themselves, downstream self-renewal pathways, and the supportive cell niche. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861166     DOI: 10.1158/1078-0432.CCR-10-0440

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  T-ALL can evolve to oncogene independence.

Authors:  Hesham Abdulla; Anh Vo; Benjamin J Shields; Tenae J Davies; Jacob T Jackson; Raed Alserihi; Elizabeth M Viney; Tin Wong; Feng Yan; Nicholas C Wong; Lisa Demoen; David J Curtis; Warren S Alexander; Pieter Van Vlierberghe; Ross A Dickins; Matthew P McCormack
Journal:  Leukemia       Date:  2021-01-22       Impact factor: 11.528

2.  LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Authors:  Tatsuya Morishima; Ann-Christin Krahl; Masoud Nasri; Yun Xu; Narges Aghaallaei; Betül Findik; Maksim Klimiankou; Malte Ritter; Marcus D Hartmann; Christian Johannes Gloeckner; Sylwia Stefanczyk; Christian Lindner; Benedikt Oswald; Regine Bernhard; Karin Hähnel; Ursula Hermanutz-Klein; Martin Ebinger; Rupert Handgretinger; Nicolas Casadei; Karl Welte; Maya Andre; Patrick Müller; Baubak Bajoghli; Julia Skokowa
Journal:  Blood       Date:  2019-07-31       Impact factor: 22.113

3.  Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.

Authors:  Elena Cubedo; Andrew J Gentles; Chuanxin Huang; Yasodha Natkunam; Shruti Bhatt; Xiaoqing Lu; Xiaoyu Jiang; Isabel Romero-Camarero; Aharon Freud; Shuchun Zhao; Carlos E Bacchi; Jose A Martínez-Climent; Isidro Sánchez-García; Ari Melnick; Izidore S Lossos
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 4.  Genetic susceptibility to neuroblastoma.

Authors:  Vanessa P Tolbert; Grace E Coggins; John M Maris
Journal:  Curr Opin Genet Dev       Date:  2017-04-28       Impact factor: 5.578

5.  LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.

Authors:  Justin H Layer; Catherine E Alford; W Hayes McDonald; Utpal P Davé
Journal:  Mol Cell Biol       Date:  2015-11-23       Impact factor: 4.272

6.  Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.

Authors:  LiQi Li; Apratim Mitra; Kairong Cui; Bin Zhao; Seeyoung Choi; Jan Y Lee; Daniel B Stamos; Dalal El-Khoury; Claude Warzecha; Karl Pfeifer; Joyce Hardwick; Keji Zhao; Bryan Venters; Utpal P Davé; Paul E Love
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

7.  Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.

Authors:  B J Shields; R Alserihi; C Nasa; C Bogue; W S Alexander; M P McCormack
Journal:  Leukemia       Date:  2014-10-06       Impact factor: 11.528

8.  Array-CGH as an adjuvant tool in cytogenetic diagnosis of pediatric MDS and JMML.

Authors:  Amanda Gonçalves Silva; Mariana Maschietto; Daniel Onofre Vidal; Leandro Mota Peliçario; Elvira Deolinda Rodrigues Pereira Velloso; Luiz Fernando Lopes; Ana Cristina Krepischi; Carla Rosenberg
Journal:  Med Oncol       Date:  2013-10-02       Impact factor: 3.064

Review 9.  LIM-domain-only proteins in cancer.

Authors:  Jacqueline M Matthews; Krystal Lester; Soumya Joseph; David J Curtis
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

10.  Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2012-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.